The US FDA has approved Abecma (ide-cel); the first CAR-T for a non-CD19 target and the second cell therapy in eight weeks for Bristol-Myers Squibb.
This weekend, the US Food and Drug Administration (FDA) approved Abecma (idecabtagene vicleucel, commonly referred to as ide-cel) as the first cell-based gene therapy for the treatment of multiple myeloma.
Developed by Bristol-Myers Squibb acquisition Celgene and fellow advanced therapy maker bluebird bio, Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy.
The autologous therapy is made using a patientâs own T-cells, which are collected and separated by apheresis, before being engineered to include a new gene that facilitates targeting and killing myeloma cells based on a modified lentivirus.
Going forward, Bristol-Myers will produce Abecma from its cellular immunotherapy manufacturing facility in Summit, New Jersey.
Rekindling of the CAR-T industry
The news represents a series of firsts in the healthcare space; the first CAR-T approval for a non-CD19 target (BCMA), the first CAR-T for relapsed or refractory (r/r) multiple myeloma, and â for Bristol-Myers â the first company to attain approval for two CAR-T products targeting different disease areas.
In February, Bristol-Myers won US approval for Breyanzi (lisocabtagene maraleucel, aka liso-cel) for the treatment of large B-cell lymphoma (LBCL).
But the news may hold wider repercussions for the cell and gene therapy sector according to Anthony Davies, founder and CEO at Dark Horse Consulting.
Writing on LinkedIn following the approval, he noted that while the first two CAR-T therapies â Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) â were approved in 2017, the momentum has since slowed down, indicating perhaps that the industry went off on a false start.
Though 2018 saw Kymriah approved in a secondary indication, until Februaryâs approval of Breyanzi only one other CAR-T has been given the thumbs up by the FDA: Gileadâs Tecartus (brexucabtagene autoleucel) for the treatment of mantle cell lymphoma (MCL) in July 2020.
âFew of these approvals have been smooth, most often for CMC concerns, not least the delays relating to the two most recent approvals, which included a 483 for a CMO [in the manufacture of Breyanzi] and an RTF [refuse to file letter] for the original Abecma BLA submission,â he said. âAnd some of these products are believed to have ongoing CMC issues.â
However, with two CAR-T products approved in the first quarter of the year, he added a note of optimism: âPerhaps we are turning a corner here, and 2021 will be the year that cell and gene therapy approvals resume the rate we all hoped for back in 2017.â
2021 and beyond
Within just the multiple myeloma space, 2021 could see another CAR-T approved in the firm of J&J/Legend Biotechâs ciltacabtagene autoleucel (cilta-cel). Accelerated assessment of the Marketing Authorisation Application (MAA) was granted last month, and according to Luca Issi, an analyst at RBC Capital Markets, approval by the year end could be possible.
Development âis likely only a few months behind,â he wrote in a note, adding it could bring bad news for Bristol-Myers as J&J and Legend have âdirectionally superior dataâ for its candidate than Abecma.
Meanwhile, according to the Alliance for Regenrative Medicine annual report, there were 25 cell-based immuno-oncology candidatesin Phase III clinical trials in 2020.